JP2008510728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510728A5 JP2008510728A5 JP2007528089A JP2007528089A JP2008510728A5 JP 2008510728 A5 JP2008510728 A5 JP 2008510728A5 JP 2007528089 A JP2007528089 A JP 2007528089A JP 2007528089 A JP2007528089 A JP 2007528089A JP 2008510728 A5 JP2008510728 A5 JP 2008510728A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- substituted
- optionally
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 37
- 125000001424 substituent group Chemical group 0.000 claims 33
- -1 cycloaliphatic Chemical group 0.000 claims 24
- 125000002950 monocyclic group Chemical group 0.000 claims 17
- 125000005843 halogen group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004993 haloalkoxycarbonyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000006168 tricyclic group Chemical group 0.000 claims 6
- 229930004006 tropane Natural products 0.000 claims 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical group C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000033 alkoxyamino group Chemical group 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 2
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 150000003813 tropane derivatives Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000006218 bradycardia Diseases 0.000 claims 1
- 230000036471 bradycardia Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000027119 gastric acid secretion Effects 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000000975 dye Substances 0.000 description 5
- JANXZPFHGIMWSD-UHFFFAOYSA-N 7-oxabicyclo[2.2.1]hept-3-ene Chemical compound C1C(O2)CCC2=C1 JANXZPFHGIMWSD-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 4
- 229960003081 probenecid Drugs 0.000 description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 0 C*(CC(*)(*)*1)C(C)(*)c2c1cccc2 Chemical compound C*(CC(*)(*)*1)C(C)(*)c2c1cccc2 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- PTPUOMXKXCCSEN-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-dichloro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O PTPUOMXKXCCSEN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60273104P | 2004-08-19 | 2004-08-19 | |
| PCT/US2005/029780 WO2006023852A2 (en) | 2004-08-19 | 2005-08-19 | Modulators of muscarinic receptors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012039210A Division JP2012107055A (ja) | 2004-08-19 | 2012-02-24 | ムスカリン受容体のモジュレーター |
| JP2012039208A Division JP2012107054A (ja) | 2004-08-19 | 2012-02-24 | ムスカリン受容体のモジュレーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008510728A JP2008510728A (ja) | 2008-04-10 |
| JP2008510728A5 true JP2008510728A5 (enExample) | 2008-08-28 |
Family
ID=35447987
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528089A Pending JP2008510728A (ja) | 2004-08-19 | 2005-08-19 | ムスカリン受容体のモジュレーター |
| JP2012039208A Withdrawn JP2012107054A (ja) | 2004-08-19 | 2012-02-24 | ムスカリン受容体のモジュレーター |
| JP2012039210A Withdrawn JP2012107055A (ja) | 2004-08-19 | 2012-02-24 | ムスカリン受容体のモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012039208A Withdrawn JP2012107054A (ja) | 2004-08-19 | 2012-02-24 | ムスカリン受容体のモジュレーター |
| JP2012039210A Withdrawn JP2012107055A (ja) | 2004-08-19 | 2012-02-24 | ムスカリン受容体のモジュレーター |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7879834B2 (enExample) |
| EP (3) | EP1781288A2 (enExample) |
| JP (3) | JP2008510728A (enExample) |
| KR (1) | KR20070046929A (enExample) |
| CN (1) | CN101031296A (enExample) |
| AU (1) | AU2005277126A1 (enExample) |
| CA (1) | CA2577677A1 (enExample) |
| IL (1) | IL181388A0 (enExample) |
| MX (1) | MX2007002033A (enExample) |
| NO (1) | NO20071272L (enExample) |
| NZ (1) | NZ553202A (enExample) |
| RU (1) | RU2007109794A (enExample) |
| TW (1) | TW200621244A (enExample) |
| WO (1) | WO2006023852A2 (enExample) |
| ZA (1) | ZA200701397B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003268512A1 (en) | 2002-09-09 | 2004-03-29 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| US7879834B2 (en) * | 2004-08-19 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Spiroindoline modulators of muscarinic receptors |
| EP2522669B1 (en) * | 2005-06-02 | 2016-12-28 | Janssen Pharmaceutica NV | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators |
| WO2007028638A1 (en) | 2005-09-09 | 2007-03-15 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
| CA2634456A1 (en) * | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| RU2008137583A (ru) * | 2006-02-22 | 2010-03-27 | Вертекс Фармасьютикалз Инкорпорейшн (Us) | Спиропиперидины в качестве модуляторов мускариновых рецепторов |
| US8003660B2 (en) * | 2006-02-22 | 2011-08-23 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
| US7858790B2 (en) * | 2006-06-29 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US7786107B2 (en) * | 2006-08-18 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| EP2064187A2 (en) | 2006-08-25 | 2009-06-03 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| CN103202840B (zh) * | 2006-11-28 | 2015-02-11 | 詹森药业有限公司 | 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐 |
| WO2008121066A1 (en) * | 2007-03-30 | 2008-10-09 | Astrazeneca Ab | Novel tricyclic spiropiperidines or spiropyrrolidines and their use as modulators of chemokine receptors |
| EP2150552B1 (en) | 2007-04-09 | 2013-01-02 | Janssen Pharmaceutica NV | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
| EP2190286A4 (en) * | 2007-08-14 | 2011-06-01 | Glaxo Group Ltd | SPIROINDENES AND SPIROINDANES AS MODULATORS OF CHEMOKINE RECEPTORS |
| JP2010540640A (ja) | 2007-10-03 | 2010-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ムスカリン作用性レセプターのモジュレーター |
| CN102464663B (zh) * | 2010-11-11 | 2015-05-27 | 上海合全药物研发有限公司 | 1’-叔丁氧羰基-螺[苯并二氢吡喃-4,4’-哌啶]-2-甲酸的合成方法 |
| US9745253B2 (en) | 2015-03-13 | 2017-08-29 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
| AR105911A1 (es) | 2015-09-03 | 2017-11-22 | Forma Therapeutics Inc | Inhibidores de hdac8 bicíclicos fusionados [6,6] |
| CN108264535A (zh) | 2016-12-30 | 2018-07-10 | 中国科学院上海药物研究所 | 一种抗抑郁化合物及其制备方法和应用 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654287A (en) * | 1970-08-26 | 1972-04-04 | Mead Johnson & Co | Spiroindanylpiperidines |
| US3666764A (en) * | 1970-08-26 | 1972-05-30 | Mead Johnson & Co | Spiroindenylpiperidines |
| DK145949C (da) | 1973-09-28 | 1983-09-26 | Ciba Geigy Ag | Analogifremgangsmaade til fremstilling af i 3-stillingen substituerede rifamycin s-forbindelser eller sv-forbindelser eller syreadditionssalte eller kvaternaere ammoniumsalte deraf |
| US3959475A (en) * | 1973-12-12 | 1976-05-25 | American Hoechst Corporation | Substituted 1,3-dihydrospiro(isobenzofuran)s |
| US3962259A (en) * | 1973-12-12 | 1976-06-08 | American Hoechst Corporation | 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof |
| US3982259A (en) * | 1974-12-13 | 1976-09-21 | Edward Van Baerle | Photographic material processing module |
| JPS54109983A (en) * | 1978-02-13 | 1979-08-29 | Sumitomo Chem Co Ltd | Novel spiroamine derivative and its preparation |
| GB1575800A (en) | 1978-05-16 | 1980-10-01 | Sumitomo Chemical Co | Spiro amines their production and compositions containing them |
| US4349549A (en) * | 1981-05-18 | 1982-09-14 | Syntex (U.S.A.) Inc. | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s |
| JPS5815979A (ja) | 1981-07-11 | 1983-01-29 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体およびその製造法 |
| JPS5959685A (ja) | 1982-09-28 | 1984-04-05 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| US4558049A (en) * | 1982-11-24 | 1985-12-10 | Farmitalia Carlo Erba S.P.A. | Antipsycotic benzoxazines |
| SE445649B (sv) * | 1983-06-08 | 1986-07-07 | Jorgen Hermansson | Anvendning av en fast berare med immobiliserad orosomucoid for separation, forfarande for framstellning av separationsmaterial, separationsanordning samt separationsmaterial |
| GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| US5091387A (en) * | 1990-03-02 | 1992-02-25 | Merck & Co., Inc. | Spirocyclic oxytocin antagonists |
| CA2037357A1 (en) | 1990-03-02 | 1991-09-03 | Ben E. Evans | Methods for using spirocyclic oxytocin antagonists |
| EP0445974A3 (en) * | 1990-03-05 | 1992-04-29 | Merck Sharp & Dohme Ltd. | Spirocyclic antipsychotic agents |
| IL99957A0 (en) | 1990-11-13 | 1992-08-18 | Merck & Co Inc | Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them |
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| US5693643A (en) * | 1991-09-16 | 1997-12-02 | Merck & Co., Inc. | Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists |
| EP0533243B1 (en) * | 1991-09-16 | 1997-12-17 | Merck & Co. Inc. | Hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives |
| DK78692D0 (da) * | 1992-06-12 | 1992-06-12 | Lundbeck & Co As H | Dimere piperidin- og piperazinderivater |
| US5578593A (en) * | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| SK282166B6 (sk) * | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
| WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
| US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
| US5457207A (en) * | 1993-10-05 | 1995-10-10 | Regents Of The University Of Minnesota | Spirovesamicols |
| AU8083694A (en) | 1993-10-19 | 1995-05-08 | Merck & Co., Inc. | Combination of bisphosphonates and growth hormone secretagogues |
| JPH09505310A (ja) * | 1993-11-16 | 1997-05-27 | メルク エンド カンパニー インコーポレーテッド | ピペリジンショウノウスルホニルオキシトシン拮抗剤 |
| WO1995028389A1 (en) | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Spiro compound and medicinal composition thereof |
| GB9421003D0 (en) | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| US5741789A (en) * | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5789402A (en) * | 1995-01-17 | 1998-08-04 | Eli Lilly Company | Compounds having effects on serotonin-related systems |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| US6130217A (en) * | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
| GB2308064A (en) | 1995-10-31 | 1997-06-18 | Merck & Co Inc | Treatment of congestive heart failure with a growth hormone secretagogue |
| RU2135494C1 (ru) * | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
| GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| AU711884B2 (en) | 1996-05-07 | 1999-10-21 | Merck & Co., Inc. | Enhancement of sleep with a growth hormone secretagogue |
| WO1997041878A1 (en) | 1996-05-07 | 1997-11-13 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
| KR20010022414A (ko) | 1997-07-31 | 2001-03-15 | 진 엠. 듀발 | Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물 |
| EP1009405A4 (en) * | 1997-08-28 | 2001-05-09 | Merck & Co Inc | PAYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY |
| US6013652A (en) | 1997-12-04 | 2000-01-11 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin antagonists |
| AU2206699A (en) * | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| GB9810886D0 (en) * | 1998-05-13 | 1998-07-22 | Lilly Industries Ltd | Pharmaceutical compounds |
| US6294534B1 (en) * | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| ID29137A (id) | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
| CA2338804A1 (en) | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Propenamides as ccr5 modulators |
| PL345713A1 (en) | 1998-07-28 | 2002-01-02 | Smithkline Beecham Corp | Substituted anilide compounds and methods |
| CA2356269A1 (en) | 1998-12-24 | 2000-07-06 | Yoshihisa Akiyama | Pain control agent |
| ITMI991452A1 (it) | 1999-07-01 | 2001-01-01 | Mediolanum Farmaceutici Srl | Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica |
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| US6803372B2 (en) * | 1999-08-20 | 2004-10-12 | Banyu Pharmaceutical Co., Ltd. | Spiro compounds |
| GB2355264A (en) * | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| GB2355456A (en) * | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| AU7716600A (en) | 1999-09-30 | 2001-04-30 | Merck & Co., Inc. | Spiro[bicyclic -azacycloalkyl and -cycloalkyl] derivatives and uses thereof |
| AU7952800A (en) | 1999-10-22 | 2001-04-30 | Sankyo Company Limited | 2-alkoxybenzene derivatives |
| WO2001045707A1 (en) | 1999-12-21 | 2001-06-28 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU2001243394A1 (en) | 2000-03-02 | 2001-09-12 | Smith Kline Beecham Corporation | Compounds and methods |
| JP2001278886A (ja) | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | ベンゾオキサジン誘導体及びこれを含有する医薬 |
| US6720324B2 (en) * | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
| JP2004520299A (ja) * | 2000-12-12 | 2004-07-08 | ニューロジェン・コーポレーション | スピロ［イソベンゾフラン−１，４’−ピペリジン］−３−オン類及び３ｈ−スピロイソベンゾフラン−１，４’−ピペリジン類 |
| EP1363898A4 (en) * | 2001-03-02 | 2004-12-08 | Bristol Myers Squibb Co | COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP2033644A1 (en) * | 2001-04-18 | 2009-03-11 | Euro-Celtique S.A. | Spiroindene and spiroindane compounds |
| WO2002088089A1 (en) * | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| JP2002316987A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ２−アルコキシベンゼン誘導体を含有する医薬 |
| WO2002094825A1 (en) | 2001-05-22 | 2002-11-28 | Banyu Pharmaceutical Co., Ltd. | Novel spiropiperidine derivative |
| ATE427935T1 (de) * | 2001-08-07 | 2009-04-15 | Banyu Pharma Co Ltd | Spiro isobenzofurane als neuropeptid y rezeptor antagonisten |
| AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| AU2002351733A1 (en) * | 2001-12-19 | 2003-06-30 | H. Lundbeck A/S | 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives |
| EP1470126A1 (en) * | 2002-01-28 | 2004-10-27 | Pfizer Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| WO2003095427A1 (en) | 2002-05-10 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Spiro-ring compound |
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
| US7105526B2 (en) * | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| UA77814C2 (en) | 2002-07-03 | 2007-01-15 | Lundbeck & Co As H | Spirocyclic piperidines as antagonists of mch1 and use thereof |
| AU2003254177A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
| WO2004010943A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
| WO2004010942A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted heterocyclic compounds as modulators of the ccr5 receptor |
| PT2208727E (pt) | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| US7045527B2 (en) * | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
| WO2004050652A1 (ja) | 2002-11-29 | 2004-06-17 | Banyu Pharmaceutical Co., Ltd. | 新規アゾール誘導体 |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| WO2004054582A1 (en) * | 2002-12-13 | 2004-07-01 | Neurogen Corporation | Combination therapy for the treatment of pain |
| SE0300458D0 (sv) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| WO2004082682A1 (en) | 2003-03-18 | 2004-09-30 | Merck & Co. Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
| CA2520114A1 (en) * | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| CN1297557C (zh) | 2003-04-10 | 2007-01-31 | 上海药明康德新药开发有限公司 | 螺环类模板化合物的制备 |
| US7414055B2 (en) | 2003-04-24 | 2008-08-19 | Merck & Co., Inc. | Inhibitors of Akt activity |
| JP4093140B2 (ja) | 2003-08-05 | 2008-06-04 | 豊田合成株式会社 | 頭部保護エアバッグ装置 |
| WO2005016913A1 (en) * | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| JP2007524568A (ja) | 2003-12-05 | 2007-08-30 | ブリストル−マイヤーズ スクイブ カンパニー | カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト |
| BRPI0417749A (pt) | 2003-12-22 | 2007-04-10 | Acadia Pharm Inc | composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas |
| AU2004309419A1 (en) * | 2003-12-23 | 2005-07-14 | Arena Pharmaceuticals, Inc. | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| EP1716156A2 (en) * | 2004-02-10 | 2006-11-02 | F.Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
| TW200533398A (en) * | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| WO2005097788A2 (en) * | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| US7279471B2 (en) * | 2004-04-15 | 2007-10-09 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| EP1753740A2 (en) | 2004-05-21 | 2007-02-21 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| AU2005249494A1 (en) | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| US7879834B2 (en) * | 2004-08-19 | 2011-02-01 | Vertex Pharmaceuticals Incorporated | Spiroindoline modulators of muscarinic receptors |
| CA2579204A1 (en) | 2004-09-07 | 2006-03-16 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
| US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
-
2005
- 2005-08-19 US US11/208,386 patent/US7879834B2/en active Active
- 2005-08-19 NZ NZ553202A patent/NZ553202A/en not_active IP Right Cessation
- 2005-08-19 MX MX2007002033A patent/MX2007002033A/es not_active Application Discontinuation
- 2005-08-19 JP JP2007528089A patent/JP2008510728A/ja active Pending
- 2005-08-19 EP EP05792897A patent/EP1781288A2/en not_active Withdrawn
- 2005-08-19 CN CNA2005800325784A patent/CN101031296A/zh active Pending
- 2005-08-19 KR KR1020077006166A patent/KR20070046929A/ko not_active Withdrawn
- 2005-08-19 CA CA002577677A patent/CA2577677A1/en not_active Abandoned
- 2005-08-19 EP EP11155136A patent/EP2364705A3/en not_active Withdrawn
- 2005-08-19 EP EP11155135A patent/EP2374455A3/en not_active Withdrawn
- 2005-08-19 TW TW094128467A patent/TW200621244A/zh unknown
- 2005-08-19 AU AU2005277126A patent/AU2005277126A1/en not_active Abandoned
- 2005-08-19 WO PCT/US2005/029780 patent/WO2006023852A2/en not_active Ceased
- 2005-08-19 RU RU2007109794/04A patent/RU2007109794A/ru not_active Application Discontinuation
-
2007
- 2007-02-15 IL IL181388A patent/IL181388A0/en unknown
- 2007-02-16 ZA ZA200701397A patent/ZA200701397B/xx unknown
- 2007-03-08 NO NO20071272A patent/NO20071272L/no not_active Application Discontinuation
-
2010
- 2010-05-24 US US12/785,676 patent/US8258148B2/en not_active Expired - Fee Related
-
2012
- 2012-02-24 JP JP2012039208A patent/JP2012107054A/ja not_active Withdrawn
- 2012-02-24 JP JP2012039210A patent/JP2012107055A/ja not_active Withdrawn
- 2012-07-11 US US13/546,185 patent/US8497295B2/en not_active Expired - Fee Related
-
2013
- 2013-06-17 US US13/919,369 patent/US20130281476A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4378597B2 (ja) | カルボン酸誘導体化合物およびそれらを有効成分とする薬剤 | |
| JP2009521483A5 (enExample) | ||
| RU2529868C2 (ru) | Производное индолизина и его применение в медицинских целях | |
| AU2014290411B2 (en) | Sulfonamides as modulators of sodium channels | |
| WO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
| US6642224B1 (en) | Diazepan derivatives or salts thereof | |
| HU227862B1 (en) | Ortho substituted benzene and pyridine derivatives and pharmaceutical compositions containing them | |
| JP4596314B2 (ja) | β−アラニン誘導体およびその用途 | |
| DK2998296T3 (en) | CYCLOYLIC ACID DERIVATIVE, PROCEDURE FOR PREPARING THEREOF AND PHARMACEUTICAL USE THEREOF | |
| JP7083826B2 (ja) | ２－置換アミノ－ナフト［１，２－ｄ］イミダゾール－５－オン化合物またはその製薬学上許容される塩 | |
| WO1996004248A1 (en) | Imidazolidine derivative and use thereof | |
| JP2009530281A (ja) | 代謝障害の治療に有用である二環式カルボン酸誘導体 | |
| JP2014525443A (ja) | キヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法 | |
| TW200822924A (en) | Pyrazoline compounds | |
| WO2012012322A1 (en) | Substituted hydroxamic acids and uses thereof | |
| TW200302719A (en) | MCH antagonists for the treatment of obesity | |
| WO2017131149A1 (ja) | テトラヒドロナフタレン誘導体 | |
| RU2007109794A (ru) | Модуляторы мускариновых рецепторов | |
| JPWO2016088834A1 (ja) | ジヒドロナフタレン誘導体 | |
| NZ576196A (en) | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia | |
| KR20020032618A (ko) | 히드록삼산 유도체 화합물, 그 제조 방법 및 그 화합물을유효 성분으로 하는 의약 | |
| WO2002066443A2 (en) | 2-thioxo-1,2,3,4-tetrahydropyrimidine derivatives | |
| ZA200106198B (en) | Polycyclic 2-amino-thiazole systems, method for the production thereof and medicament containing said compounds. | |
| CN1318053A (zh) | 用作钾通道开放剂的环戊酮二氢吡啶化合物 | |
| WO2001096309A1 (en) | Hydroxyformamidine derivatives and medicines containing the same |